Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371770 | 0.81 | MAOA (0.60) | MAOAMAOBTAAR1DPP4GAA | |
| SCHEMBL3898162 | 0.78 | MAOA (0.47) | MAOAMAOBTAAR1DPP4GAA | |
| SCHEMBL31417141 | 0.77 | MAOB (0.68) | MAOAMAOBTAAR1HDAC4DPP4 | |
| SCHEMBL1152119 | 0.77 | DPP4 (0.63) | MAOAMAOBTAAR1DPP4SMN1; SMN2 | |
| SCHEMBL1561557 | 0.77 | MAOA (0.45) | MAOAMAOBTAAR1DPP4GAA | |
| SCHEMBL7333210 | 0.77 | DPP4 (0.57) | MAOAMAOBTAAR1DPP4SMN1; SMN2 | |
| SCHEMBL6867538 | 0.77 | MAOA (0.45) | MAOAMAOBTAAR1DPP4GAA | |
| Ammonia Solution, Strong SCHEMBL7260918 | 0.76 | DPP4 (0.55) | MAOAMAOBTAAR1DPP4SMN1; SMN2 | |
| SCHEMBL2856019 | 0.76 | DPP4 (0.61) | MAOAMAOBTAAR1DPP4SMN1; SMN2 | |
| SCHEMBL29017388 | 0.75 | OPRM1 (0.34) | MAOAMAOBTAAR1DPP4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494986-B2 | Cycloalkylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-24 | — | — | US | disclosed |
| US-7276631-B2 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276631-B2 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276631-B2 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| WO-2006014664-A2 | CYCLOPENTYLAMINE AND CYCLOHEXYLAMINE DERIVATIVES AS NK-1/SSRI ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060019944-A1 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019944-A1 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | SLC6A4, SLC6A2, SLC6A1 | MAOA 329/4885MAOB 411/4885TAAR1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.